Abstract Dried blood spot (DBS) is a minimally invasive sampling method suitable for sample collection, storage and transportation in resource limited areas. Aim of this study was to compare the diagnostic utility of DBS with plasma sample for HCV RNA quantitation and genotyping using commercial systems. Plasma and DBS card spotted samples were collected from 95 HCV seropositive patients. Both types of samples were subjected to HCV RNA by real-time PCR (Abbott m2000rt, USA). Genotyping was performed using Abbott HCV genotype II kit (Abbott diagnostics, USA) in samples with viral load [ 3 log 10 IU/ ml. In both plasma and DBS, 14 (14.7%) samples were negative and 81 (85.3%) were positive for HCV RNA. Median viral load in plasma (3.78; range 0-7.43) log 10 IU/ ml was comparable to DBS (3.93; range 0-7.24) log 10 IU/ ml. DBS demonstrated sensitivity and specificity of 97.5 and 85.7% respectively, with positive predictive value (PPV) of 97.5% and negative predictive value (NPV) of 85.7%. DBS showed good correlation (r 2 = 0.866) and agreement (93.5%) with plasma. Genotyping in 20 patients showed 100% concordance between DBS and plasma samples. DBS showed good sensitivity and specificity as a sampling method for HCV RNA quantitation and genotyping.
Introduction
Hepatitis C virus (HCV) is a single strand RNA virus that belongs to the family Flaviviridae and genus Hepacivirus. An estimated 130-170 million people worldwide are chronically infected with HCV, with 3-4 million new infections reported every year and majority of these individuals live in low-and middle-income countries (LMICs) [1, 7] . Nearly half a million HCV infected individuals die annually due to absence of accessible and effective diagnostic and treatment facilities in most of these LMICs [27, 28] . Recent WHO guidelines have made it mandatory to do HCV RNA in all HCV seropositive individuals [29] . WHO also mandates acceleration of HCV screening and diagnosis to meet its global goal of eradication of HCV by 2030 [29] .
Plasma sample which is currently considered as gold standard for the performance of HCV RNA and genotyping poses a significant challenge in storage and transportation especially in peripheral health settings with limited facilities and resources. Current phlebotomy procedures are invasive, require -80°C for storage and need transportation in cold chain. Therefore new and alternative sampling tools for HCV testing with minimal storage and transport conditions must be evaluated.
Dried blood spots (DBS) present a minimally invasive sampling method for sample collection, storage and transportation making it a potential option for serological testing and nucleic acid testing (NAT) in low-resource settings [23] . It involves collection of capillary blood from a fingerprick onto a protein-saver card, which is then airdried and stored until ready for processing [5] . DBS specimens cannot leak or be broken in transit, hence the risks associated with shipping is minimised [12] . DBS collection is easy to perform, involves smaller blood volumes than venous blood and does not require trained phlebotomists [10] . It can also be transported and stored easily without the need for cold-chain transport or carriage on dry ice or in liquid nitrogen [11] . The process of centrifugation and separation of sera from blood samples is also not necessary, therefore eliminating the risks involved in the handling of potentially infected material [18] . DBS specimens can be extremely useful in specific settings, where there are either no facilities or expertise to take venous blood specimens, or there are persons with poor venous access [29] .
DBS has been validated for its use in HIV testing [13, 14, 16] , however there is limited data on its utility in HCV testing. Studies and data are also more limited for nucleic acid testing (NAT) than for serology testing [29] . There is very limited literature on the use of DBS specimens on existing commercial assays which is required for regulatory approval for use of this specimen [29] .
This study aims to assess the clinical utility of DBS as a sampling tool for HCV RNA quantitation and genotyping on commercial Abbott real-time assay and compare it with plasma which can be of great help in peripheral health settings where storage facilities and advanced set-up for molecular tests is not available. Use of DBS can be a major breakthrough for HCV diagnosis in these areas.
Materials and methods

Study design
This was a prospective cross-sectional study conducted at a tertiary liver-care institute from May to October, 2016.
Study population
Consecutive anti-HCV positive patients either attending the outpatient department (OPD) or admitted within the institute were included in the study. Patients with HIV coinfection, chronic kidney disease patients on haemodialysis and those on immunosuppressive therapy were excluded from the study.
Sample collection and storage 3-5 ml blood samples were collected from each patient by venepuncture and placed into EDTA tubes which was further divided into two portions. From first portion, 70 ll of whole blood was aspirated and spotted to each one-halfinch (12 mm) circle on a Munktell TFN filter paper card after inverting the tube several times for mixing the blood. Five circles of whole blood spots prepared for every blood sample were collected and air-dried overnight at room temperature followed by its storage in ziplock sachet with desiccant at 2-8°C. Blood samples from second portion EDTA tube was centrifuged and 500 ll of plasma was separated and stored at -80°C.
Processing of DBS samples
Processing of DBS for elution of RNA was done as per the protocol provided by the Abbott diagnostics to be used on their assay system (m2000rt, Abbott diagnostics) for HCV RNA quantitation. Briefly, the disc of dried blood was punched out from one spot circle using a hole puncher and was directly mixed with 1.3 ml extraction buffer and elution mix. The master-mix tubes were then incubated for 30 min at 55°C using a digital dry-block heater. The eluate obtained after incubation was processed like a regular plasma sample for HCV RNA viral load testing in m2000rt system, Abbott diagnostics using Abbott HCV RNA kit as per the manufacturer's instructions. The remaining eluate was stored at -80°C.
Real-time PCR for HCV RNA quantitation (Abbott Real Time HCV assay) 500 ll of plasma samples and eluates from the DBS were tested by the Abbott Real Time HCV assay on the automated m2000rt platform, as per the manufacturer's instructions. Results were expressed as IU/ml. Lower limit of detection for the assay was 12 IU/ml with a linear range of 12-10 8 IU/ml.
HCV genotyping
A subset of plasma samples and corresponding DBS eluates with viral load [ 3 log 10 IU/ml were further processed for genotyping by 'HCV GENOTYPE II' (Abbott diagnostics, USA). The Abbott Real Time HCV Genotype II assay detects genotypes 1, 2, 3, 4, 5, and 6, and subtypes 1a and 1b through the use of genotype-specific fluorescentlabeled oligonucleotide probes. It targets the 5 0 UTR for the classification of HCV genotypes 1, 2, 3, 4, 5, and 6, and the NS5B region to accurately subtype HCV genotypes 1a and 1b.
Statistical analysis
The analysis was carried out using SPSS version 22.0 (IBM Corp, Armonk; NewYork, USA). The data was represented as mean ± standard deviation or in frequencies. The agreement between DBS and plasma results was seen using intraclass coefficient correlation (ICC) followed by blandaltman analysis graph. Correlation between DBS and plasma results was carried out by regression analysis. The HCV RNA values were log 10 transformed for analysis and p value of \ 0.05 was considered as significant.
Results
Patient clinical characteristics
Of a total of 95 anti-HCV positive cases in this study, 64 (67.4%) were males with a sex ratio of 2:1. Mean age of the patients was 44.69 ± 13.3 years. Mean alanine transaminase and mean aspartate transaminase were 65 ± 44 IU/ml and 64 ± 56 IU/ml respectively. Median plasma HCV RNA viral load was 3.78 (range 0-7.43) log 10 IU/ml and median DBS HCV RNA viral load was 3.93 (range 0-7.24) log 10 IU/ml.
Comparison between the two methods in HCV RNA quantitation HCV RNA quantitation was compared for both DBS and plasma samples keeping plasma as the gold standard. 81 (85.3%) plasma samples and 81 (85.3%) DBS samples were positive for HCV RNA whereas 14 (14.7%) plasma samples and 14 (14.7%) DBS samples were negative for HCV RNA. There were 14 (14.7%) DBS samples which showed a lower limit of detection (LLOD) of 3 log 10 IU/ ml. Out of 81 plasma positive samples, 79 (97.5%) were positive by DBS as well and out of 14 plasma negative samples, 12 (85.7%) were negative by DBS. The overall concordance rate between DBS and plasma results was 95.8% (supplementary Table 1 ). Supplementary Table 2 shows the diagnostic performance of DBS testing for HCV RNA compared to plasma.
Sensitivity of DBS in different HCV RNA viral load ranges
Supplementary Table 3 depicts the sensitivity of DBS in different HCV RNA viral load ranges taking plasma as the standard. DBS showed 100% detection rate for HCV RNA with viral load of C 3 log 10 IU/ml. The total number of samples collected by DBS where exact viral load was quantitated by the commercial kit were 67 (70.5%). In 14 (14.7%) patients with plasma HCV RNA viral load between 1.08 and 3 log 10 IU/ml, though HCV RNA was detected, but a viral load of \ 3 log 10 IU/ml via DBS was obtained. Therefore, the LLOD for DBS in this study was taken as 3 log 10 IU/ml.
Evaluation of DBS cards using reference standards
High and low positive 5th WHO International standards for HCV RNA were tested three times via both plasma and DBS protocol to evaluate its precision. These reference standards were formulated from a donation of window period plasma, in order to obtain a suitable concentration following which they were reconstituted with 1.1 ml of deionized, nuclease-free molecular-grade water and left for a minimum of 20 min. Once reconstituted, the reference standards were diluted in negative human plasma followed by extraction and detection of HCV RNA via both the sample type methodologies. Results showed that variation was higher with HCV RNA viral load of 2 log 10 IU/ml but lower with 3 log 10 IU/ml onwards (supplementary Table 4 ).
Correlation and agreement between the two methods
Good linearity (correlation coefficient = R 2 0.866; p value \ 0.001) was observed between DBS and plasma log RNA values via linear regression analysis curve, demonstrating a significantly good correlation (Fig. 1) . Good agreement of 93.5% was also observed between DBS and plasma RNA values.
Bland Altmann Analysis curve was used to determine the number of cases within agreement limits by plotting the differences between DBS and plasma log values against the averages of the two techniques (Fig. 2) . Total number of cases within agreement limits in this study was 91/95 (95.8%) with a bias of 0.54 log IU/ml between DBS and plasma values.
Comparison between the two methods in HCV genotyping
HCV genotyping from 20 plasma samples with a high HCV RNA viral load of C 3 log 10 IU/ml showed the predominance of genotype 3 (70%) in the study population followed by genotype 1 (20%), genotype 4 (5%) and genotype 5 (5%) (Fig. 3) . Genotypes 2 and 6 were not found in any of the samples. HCV genotyping was successfully performed on these 20 corresponding DBS samples, with 100% concordance between the DBS and plasma samples (genotypes 1-6).
Evaluation of dried blood spot as an alternative sample collection method for hepatitis C…
Discussion
In the present study, DBS was evaluated as an alternative sample collection method to plasma for HCV RNA quantitation and genotyping using commercial Abbott real-time assay. DBS has been validated for HIV testing [13, 14, 16] , however limited literature is available regarding its utility in HCV testing [1, 3, 26] .
This study showed that the median DBS HCV RNA viral load was slightly higher as compared to the median plasma HCV RNA viral load. This can be due to the fact that there is an increased concentration of HCV RNA in whole blood relative to plasma and individual blood cell compartments [22, 25] .
In this study, sensitivity of DBS was 97.5% which was in accordance with other studies which have shown sensitivity in the range of 90-100% [5, 20, 21, 24] and 2 (2.1%) false negative cases were detected in this study both of which showed low viral load of log 2 IU/ml with plasma. These false negative results might be attributed to the low sample amount in case of DBS [4, 6, 26] .
Specificity of DBS in this study was seen at 85.7% which was slightly less than that in already available literature [5, 20, 24] . This may be because 2 (2.1%) false positive cases were detected in this study. The most plausible explanation for this discrepancy might be cross-contamination. However, all precautions to rule out crosscontamination were taken in the study. Second explanation could be the presence of HCV in B lymphocytes (as this fraction was present in whole blood which was used as a starting material) found in the DBS samples [21] and the persistence of cell-associated HCV RNA long after spontaneous clearance or successful treatment [19] . However, techniques to reduce the measurement of cell-associated virus are being developed for measurement of HIV RNA using DBS, and these same techniques may be applied to HCV DBS [30] . The two false positive cases in this study were followed up and after 3 weeks, repeat samples were collected. HCV RNA done by both DBS and plasma showed negative results for the two samples, thus depicting the possibility that DBS could show false positive results despite the absence of cross-contamination.
This study showed a good correlation between DBS and plasma HCV RNA log values which is similar to other studies [3, 26] . 95.8% cases in this study were within agreement limits via Bland Altmann Analysis curve and the result is in accordance with other studies [26] .
The lower limit of detection (LLOD) of the DBS method for HCV RNA in this study based on the results was found to be 3 log 10 IU/ml as HCV RNA viral load below this level gave variable results when compared with plasma results. LLOD of 3 log 10 IU/ml for HCV RNA was also shown by two previous studies [3, 26] whereas LLOD of 2.40 and 2.70 log 10 IU/ml were shown by Bennett et al. [1] and De Crignis et al. [4] respectively. This inability of DBS in detecting low HCV viral load may be due to lower volume of blood used in blotting DBS as compared to plasma [12] and due to lack of standardized protocol for nucleic acid extraction from DBS which is less efficient as compared to that of plasma [2, 6] . As values below 3 log 10 IU/ml are relatively uncommon in untreated patients, hence this level of sensitivity may suit pretreatment molecular HCV diagnosis [26] . According to the current WHO guidelines, people with viraemic HCV infection have high viral loads of [ 4 log 10 IU/ml, hence recommending DBS specimens for HCV RNA because they are possible and accurate within this range [29] . All samples were successfully genotyped with 100% concordance in HCV genotyping results between DBS and plasma samples which was similar with those of other studies [3, 9, 15, 17, 26] . This proves that DBS is a very reliable sampling method for HCV genotyping.
Using DBS as sampling method will definitely increase uptake of HCV testing especially in remote areas. Hickman et al. [8] reported an average increase of 14.5% in HCV testing in the intervention sites where DBS were offered as sampling method compared to their matched controls using venepuncture alone.
Although this study was conducted with utmost accuracy and precision, there was one limitation in this study. Since, this was a laboratory-based study in which patients had to give blood via venepuncture for various other investigations, hence DBS cards were not blotted via finger-prick blood and an in-house designed protocol was used and standardised using 70 ll whole blood which was pipetted onto the DBS cards.
Overall DBS methodology in this study was found to be a sensitive and specific alternative to blood testing for HCV RNA quantitation and genotyping.
Further studies, field validation and standardization of the methodology is required so that use of DBS in HCV diagnosis can be scaled-up to reach to the majority of population.
More validation studies need to be conducted on the use of DBS specimens for serology and NAT with optimal assay cut-offs and research should be done on the development of manufacturers' guidance and regulatory approval of commercial assays using DBS specimens.
